Incorporated in 1993, Artegraft Inc. offers surgeons a biological alternative to synthetic grafts. Artegraft’s natural collagen matrix has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Artegraft was the first vascular graft approved by the FDA in 1970 and has been in continuous clinical use for over 45 years. Available in lengths from 15 to 50 cm and in 4, 5, 6, 7 and 8 mm inner diameters, Artegraft is approved for use, distal to the aorta, for segmental bypass, arterial replacement, patch graft, femoropopliteal bypass when the patient’s saphenous is absent or inadequate, but is predominantly used as a hemodialysis graft.
Artegraft is positioned in the market as a biological alternative to synthetic grafts, particularly ePTFE, a thermoplastic that was never designed to be punctured 312 times per year as a hemodialysis graft. Artegraft’s natural collagen matrix, as well as its surgical versatility and compliance, has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Think of it as a Fistula in a Bottle™.
The Company is led by a management team with extensive experience in the medical device market:
Richard A. Gibson, President and Chief Executive Officer. Rick has served since 1996. Prior to Artegraft, he was the founder and chairman of ENtech, Inc. a manufacturer of enteral delivery devices used in the nutritional support of hospitalized patients, acquired by Teleflex. Rick also held sales, marketing, and business development positions with three medical device manufacturers from 1972 through 1986.
Steven L. Weinberg, Ph.D., VP of Clinical Affairs. Since 2006 and with over 40 years experience in the medical device sector, Steve has over 30 patents and publications and has contributed to several medical and biomaterial textbooks. Having a background in Mechanical/Biomedical Engineering, his expertise is in cardio/vascular devices.
Norris J. Horn, Chief Financial Officer. Norris joined the company in 2005 and serves as Chief Financial Officer. He has over 45 years of experience in all financial aspects of the healthcare field including consumer, pharma and medical devices.
Cathleen VanDerVeer, VP of Operations. Cathy has been with Artegraft for over 20 years. She has a mechanical engineering degree and is responsible for manufacturing, administration and human resources.
Warren Kirschbaum, VP of Sales. Warren has been with Artegraft since 2011. He has significant medical device sales and marketing experience and is responsible for the company’s sales and marketing functions.
Cynthia L. Salter, Director of Quality Systems. Cindy joined Artegraft in 2012 and is responsible for overseeing the Quality Management System and Quality Control. She has 20 years experience in the medical device industry, primarily Quality/Regulatory, as well as R&D and Processing.
Joseph A. Ciccone, Director of Regulatory Affairs. Joe joined the company in 2017. He brings over 18 years of experience in a broad array of regulated product categories with a focus on medical devices.